Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [14C]CPT-11 in cancer patients

Drug Metabolism and Disposition

Volumn 28, Issue 4, 2000, Pages 423-433

  Slatter, John Greg ^a   Schaaf, Larry J ^a   Sams, James P ^a   Feenstra, Kenneth L ^a   Johnson, Mark G ^a   Bombardt, Paul A ^a   Cathcart, Karen Sue ^a   Verburg, Michael T ^a   Pearson, Laura K ^a   Compton, Linda D ^a   Miller, Langdon L ^a   Baker, David S ^a   Pesheck, Caroline V ^a   Lord III, Raymond S ^b  

^a PFIZER INC   (United States)

^b West Michigan Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN;

ADULT; AGED; ARTICLE; BILE; CANCER PATIENT; CLINICAL ARTICLE; DRUG EXCRETION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; MALE; METABOLITE; PRIORITY JOURNAL; RADIOACTIVITY; SOLID TUMOR;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BILE; BIOTRANSFORMATION; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEOPLASMS;

BACTERIA (MICROORGANISMS);

EID: 0034038190     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Aiyama R, Nagai H, Sawada S, Yokokura T, Itokawa H and Nakanishi M (1992) Determination of self-association of irinotecan hydrochloride (CPT-11) in aqueous solution. Chem Pharm Bull (Tokyo) 40:2810-2813.
2. Burke TG and Mi Z (1994) The structural basis of camplothecin interactions with human serum albumin: Impact on drug stability. J Med Chem 37:40-46.
3. Chabot GG (1997) Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33:245-254.
4. Chabot GG, Abigerges D, Calimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Herait P, Armand JP, Bugat R, Clavel M and Marty ME (1995) Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141-151.
5. Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H and Sugiyama Y (1997a) Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther 281:304-314.
6. Chu XY, Kato Y and Sugiyama Y (1997b) Multiplicity of biliary excretion mechanisms for irinotecan. CPT-11, and its metabolites in rats. Cancer Res 57:1934-1938.
7. Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE and Sugiyama Y (1998) Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters. Cancer Res 58:5137-5143.
8. Code of Federal Regulations: 21 CFR 361.1 (1998) Radioactive drugs for certain research purposes (http://wwvv.counterpoint.com/CFR/21/1997/1031/0003128.html): Updated 1 April 1998. Counterpoint Publishing, Cambridge, MA.
9. Dain JG, Collins JM and Robinson WT (1994) A regulatory and industrial perspective of the use of Carbon-14 and tritium isotopes in human ADME studies. Pharm Res 11:925-928.
10. Dodds HM, Craik DJ and Rivory LP (1997) Photodegradation of Irinotecan (CPT-11) in aqueous solutions: Identification of fluorescent products and influence of solution composition. J Pharm. Sci 86:1410-1416.
11. Dodds HM, Haaz MC, Riou JF, Robert J and Rivory LP (1998) Identification of a new metabolite of CPT-11 (irinotecan) Pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 286:578-583.
12. Gole DJ, Piral JL, Kamenka JM and Domino EF (1987) Hydroxy metabolites of phencyclidine. Identification and quantitation of two novel metabolites. Drug Metab Dispos 16:386-391.
13. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE and Ratain MJ (1994) Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea. Cancer Res 54:3723-3725.
14. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE and Ratain MJ (1997) Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15:1502-1510.
15. Haaz MC, Riche C, Rivory LP and Robert J (1998a) Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin] by human hepatic microsomes. Drug Metab Dispos 26:769-774.
16. Haaz MC, Rivory LP, Riche C and Rohert J (1998b) Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 58:468-472.
17. Haaz MC, Rivory LP, Riche C and Robert J (1997) The transformation of irinotecan (CPT-11) to its active metabolite SN-38 hy human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms. Naunyn-Schmiedebergs Arch Pharmacol 356:257-262.
18. Hsiang YH, Hertzberg R, Hechi S and Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14888.
19. Jansen WJ, Zwapl B, Hulscher ST, Giaccione G, Pinedo HM and Bouen E (1997) CPT-11 in human colon-cancer cell lines and xenografts. Characterization of cellular sensitivity determinants. Int J Cancer 70:335-340.
20. Kaneda N, Nagata H, Furuta T and Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Rez 50:1715-1720.
21. Kaneda N and Yokokura T (1990) Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721-1725.
22. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191.
23. Kono A and Hara Y (1991) Conversion of CPT-11 into SN-38 in human tissues. Jpn J Cancer Chemother 18:2175-2178.
24. Kothe MJC, Bakker CTM, de Haan J, Maas A, Jansen PLM and Qude Elferink RPJ (1993) Canalicular organic anion transport after bile duct ligation and reconstruction in the rat. Hepatology 18:138A (abstract).
25. Kunimoto T, Nitta K, Tanaka T, Uehura N, Baha H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T and Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidinoi-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin. against murine tumors. Cancer Res 47:5944-5947.
26. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF (1996) Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 23(Suppl 3):11-20.
27. Loevinger R, Budlinger TF and Watson EE (1991) MIRD primer for absorbed dose calculations. Revised Edition. Society of Nuclear Medicine, New York.
28. Lokiec F, Canal P, Gay C, Chatelut E, Armand JP, Roche H, Bugat R, Goncalves E and Mathieu-Boue A (1995) Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol 36:79-82.
29. Lokiec F, du Sordier BM and Sanderink GJ (1996) Irinotecan (CPT-11) metabolites in human bile and urine. Clin Cancer Res 2:1943-1949.
30. Masumoto H, Ohta S and Hirobe M (1991) Application of chemical cytochrome P-450 model systems to studies on drug metabolism. IV. Mechanism of piperidine metabolism pathways via an iminium intermediate Drug Metab Dispos 19:768-779.
31. Rivory LP, Haaz M-C, Canal P, Lokiec F, Armand J-P and Robert J (1997) Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials. Clin Cancer Res 3:1261-1266.
32. Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Cummercon A, Pond SM and Robert J (1996) Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 56:3689-3694.
33. Rivory LP and Robert J (1995) Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 36:176-179.
34. Rothenberg ML, Kuhn JG, Burris HA 3d, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK and Von Hoff DD (1993) Phase I and pharmacokinetic trial of weekly CPT 11. J Clin Oncol 11:2194-2204.
35. Sawada S, Okajima S, Aiyama R, Nokata K, Furuta T, Yokokura T, Sugino H, Yamaguchi K and Miyasaka T (1991) Synthesis and antitumor activity of 20(S)-camptothecin derivatives: Carbamate-linked, water soluble prodrugs of 7-ethyl -10-hydroxycamptothecin. Chem Pharm Bull 39:1446-1454.
36. Scott DO, Bindra DS and Stella VJ (1993a) Plasma pharmacokinetics of the lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats. Pharm Res 10:1451-1457.
37. Scott DO, Bindra DS, Sutton SC and Stella VJ (1993b) Urinary and biliary disposition of the lactone and carboxylate forms of 20(S)-camptothecin in rats. Drug Metab Dispos 22:438-442.
38. Slatter JG, Su P, Sams JP, Schaaf LJ and Wienkers LC (1997) Bioactivation of the anticancer agent irinotecan (CPT-11) to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 25:1157-1164.
39. Sparreboom A, de Jonge MJA, de Bruijn P, Brouwer E, Nooter K, Loos WJ, van Alphen RJ, Mathijssen RHJ, Stoler G and Verweij J (1998) Irinotecan (CPT-11) metabolism and disposition in cancer patients Clin Cancer Res 4:2747-2754.
40. Sun JXS, Embil K, Chow DSL and Lee CCS (1987) High-performance liquid Chromatographic analysis, plasma protein binding and red blood cell partitioning of phenprobamate. Biopharm Drug Dispos 8:341-351.
41. Yoshida A, Ueda T, Wano Y and Nakamura T (1993) DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells. Jpn J Cancer Res 85:566-573.